Treating prolactinomas with dopamine agonists: always worth the gamble?

Sean Noronha; Victoria Stokes; Niki Karavitaki; Ashley Grossman

doi:10.1007/s12020-015-0727-2

Treating prolactinomas with dopamine agonists: always worth the gamble?

Sean Noronha, Victoria Stokes, Niki Karavitaki, Ashley Grossman

Metabolism and Systems Research

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

Original language	English
Journal	Endocrine
Early online date	4 Sept 2015
DOIs	https://doi.org/10.1007/s12020-015-0727-2
Publication status	E-pub ahead of print - 4 Sept 2015

Keywords

Bromocriptine
Cabergoline
Impulse control
Gambling
Hypersexuality

Access to Document

10.1007/s12020-015-0727-2Licence: None: All rights reserved

Cite this

@article{84c8fea0125d4bd7b93c5aea7c7df7ec,

title = "Treating prolactinomas with dopamine agonists: always worth the gamble?",

abstract = "Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.",

keywords = "Bromocriptine, Cabergoline, Impulse control, Gambling, Hypersexuality",

author = "Sean Noronha and Victoria Stokes and Niki Karavitaki and Ashley Grossman",

year = "2015",

month = sep,

day = "4",

doi = "10.1007/s12020-015-0727-2",

language = "English",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Springer",

}

TY - JOUR

T1 - Treating prolactinomas with dopamine agonists

T2 - always worth the gamble?

AU - Noronha, Sean

AU - Stokes, Victoria

AU - Karavitaki, Niki

AU - Grossman, Ashley

PY - 2015/9/4

Y1 - 2015/9/4

N2 - Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

AB - Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

KW - Bromocriptine

KW - Cabergoline

KW - Impulse control

KW - Gambling

KW - Hypersexuality

U2 - 10.1007/s12020-015-0727-2

DO - 10.1007/s12020-015-0727-2

M3 - Article

C2 - 26336835

SN - 1355-008X

JO - Endocrine

JF - Endocrine

ER -

Treating prolactinomas with dopamine agonists: always worth the gamble?

Abstract

Keywords

Access to Document

Fingerprint

Cite this